Mirati Therapeutics (DB:26M) - Cotización, noticias y análisis

Resumen de acción 26M

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.

Acerca de la empresa

26M fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 80.9% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los ingresos de 50.16%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Mirati Therapeutics, Inc.

MorphoSys

XTRA:MOR

€2.5b

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€682.6m

Heidelberg Pharma

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Mirati Therapeutics
Historical stock prices
Current Share Price	US$53.30
52 Week High	US$59.46
52 Week Low	US$25.13
Beta	0.77
1 Month Change	0.95%
3 Month Change	2.74%
1 Year Change	22.25%
3 Year Change	-69.72%
5 Year Change	-1.55%
Change since IPO	247.67%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	26M	DE Biotechs	Mercado DE
7D	-2.0%	-5.9%	-1.7%
1Y	22.2%	-21.4%	-0.2%

Rentabilidad vs. Industria: 26M superó al sector German Biotechs , que obtuvo un rendimiento del -23.1% el año pasado.

Rentabilidad vs. Mercado: 26M superó al mercado German, que obtuvo un rendimiento del 5.9% el año pasado.

Volatilidad de los precios

Is 26M's price volatile compared to industry and market?
26M volatility
26M Average Weekly Movement	1.4%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 26M no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 26MLa volatilidad semanal ha disminuido de 10% a 2% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1995	587	Chuck Baum	www.mirati.com

Resumen de fundamentos de Mirati Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Mirati Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de 26M
Capitalización bursátil	€3.79b
Beneficios(TTM)	-€668.10m
Ingresos (TTM)	€35.15m

107.8x

Ratio precio-ventas (PS)

-5.7x

Ratio precio-beneficio (PE)

¿Está 26M sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 26M
Ingresos	US$38.19m
Coste de los ingresos	US$510.48m
Beneficio bruto	-US$472.29m
Otros gastos	US$253.59m
Beneficios	-US$725.88m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-10.35
Margen bruto	-1,236.66%
Margen de beneficio neto	-1,900.65%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 26M a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 26M

Recompensas

Análisis de riesgos

Competidores de Mirati Therapeutics, Inc.

XTRA:MOR

€2.5b

XTRA:BIO3

€1.4b

XTRA:FYB

€682.6m

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Insufficient new directors

Second quarter 2023 earnings released: US$3.04 loss per share (vs US$3.18 loss in 2Q 2022)

New minor risk - Insider selling

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Chief Financial Officer recently sold €161k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO & Director recently sold €125k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold €160k worth of stock

Executive VP & Chief Scientific Officer recently sold €98k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Executive VP & Chief Scientific Officer recently sold €148k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Mirati Therapeutics, Inc. Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C -Mutated Gastrointestinal Cancers

Chief Commercial Officer recently sold €67k worth of stock

Chief Commercial Officer recently sold €235k worth of stock

Chief Scientific Officer recently sold €139k worth of stock

High number of new directors

High number of new directors

Independent Director Michael Grey has left the company

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2000 Growth Index

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation

Chief Scientific Officer recently sold €55k worth of stock

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Rentabilidad de los accionistas

Volatilidad de los precios